What Researchers Did
This study reviewed the established role and benefits of hyperbaric oxygen therapy (HBOT) as an adjunctive treatment for necrotizing soft tissue infection (NSTI).
What They Found
Researchers found that hyperbaric oxygen therapy (HBOT) offers direct benefits such as bacteriostasis, disruption of bacterial toxin production, and attenuation of inflammation in necrotizing soft tissue infection (NSTI). Indirectly, HBOT enhances surgical efforts by demarcating viable tissue, potentiates antibiotics, and improves immune system function, leading to demonstrated benefits in morbidity and mortality.
What This Means for Canadian Patients
Canadian patients with necrotizing soft tissue infection (NSTI) may benefit from considering hyperbaric oxygen therapy (HBOT) as an adjunctive treatment. This therapy, which is generally well tolerated, could enhance recovery and improve outcomes when incorporated into multidisciplinary management.
Canadian Relevance
This study does not have a direct Canadian connection as it was not conducted in Canada, nor does it specifically address the Canadian healthcare context.
Study Limitations
This abstract, being a discussion of HBOT's role, does not present new primary research data or specific study limitations.